Equities research analysts predict that Insys Therapeutics Inc (NASDAQ:INSY) will announce ($0.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Insys Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.12). Insys Therapeutics reported earnings of $0.03 per share in the same quarter last year, which suggests a negative year over year growth rate of 600%. The business is expected to report its next earnings results on Thursday, August 2nd.

On average, analysts expect that Insys Therapeutics will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.64) to ($0.58). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.27) per share, with EPS estimates ranging from ($0.33) to ($0.20). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Insys Therapeutics.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01). Insys Therapeutics had a negative net margin of 188.01% and a negative return on equity of 43.27%. The business had revenue of $23.90 million for the quarter, compared to analyst estimates of $25.82 million. During the same quarter in the previous year, the firm posted ($0.09) earnings per share. The business’s revenue was down 33.4% on a year-over-year basis.

INSY has been the subject of several analyst reports. ValuEngine cut shares of Insys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Cann reiterated an “average” rating on shares of Insys Therapeutics in a research note on Friday, March 2nd. Piper Jaffray Companies cut shares of Insys Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Friday, March 9th. Oppenheimer reiterated a “hold” rating on shares of Insys Therapeutics in a research note on Sunday, March 11th. Finally, Zacks Investment Research upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 10th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. Insys Therapeutics currently has an average rating of “Hold” and a consensus price target of $9.38.

Insys Therapeutics traded down $0.32, hitting $7.83, on Friday, according to Marketbeat.com. 14,090 shares of the company’s stock traded hands, compared to its average volume of 916,467. Insys Therapeutics has a 1-year low of $4.10 and a 1-year high of $14.00. The stock has a market cap of $601.54 million, a price-to-earnings ratio of -16.43 and a beta of 1.09.

In other news, Director Brian Tambi sold 166,504 shares of the company’s stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $6.41, for a total transaction of $1,067,290.64. Following the completion of the sale, the director now owns 4,000 shares of the company’s stock, valued at $25,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 67.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Stone Ridge Asset Management LLC purchased a new stake in shares of Insys Therapeutics in the fourth quarter valued at about $137,000. Virtu Financial LLC boosted its stake in Insys Therapeutics by 96.8% during the fourth quarter. Virtu Financial LLC now owns 20,061 shares of the specialty pharmaceutical company’s stock worth $193,000 after buying an additional 9,866 shares during the period. JPMorgan Chase & Co. boosted its stake in Insys Therapeutics by 303.5% during the first quarter. JPMorgan Chase & Co. now owns 25,624 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 19,273 shares during the period. Raymond James & Associates boosted its stake in Insys Therapeutics by 93.5% during the fourth quarter. Raymond James & Associates now owns 31,008 shares of the specialty pharmaceutical company’s stock worth $298,000 after buying an additional 14,982 shares during the period. Finally, Deutsche Bank AG boosted its stake in Insys Therapeutics by 116.1% during the fourth quarter. Deutsche Bank AG now owns 53,827 shares of the specialty pharmaceutical company’s stock worth $515,000 after buying an additional 28,923 shares during the period. 17.78% of the stock is owned by hedge funds and other institutional investors.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.